Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB099318 in advanced solid tumors
NCT04272034Phase 1Terminated
- Sponsor
- Incyte
- Start
- Mar 2021
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label trial of incb099318 in solid tumor (advanced stage), cutaneous squamous cell carcinoma (cSCC), urothelial carcinoma (UC) and 13 more (3 cohorts), sponsored by Incyte. Primary endpoint: Treatment-Emergent Adverse Events at 25 months. Started Mar 2021; status: terminated.
02
Drugs
incb099318
03
Conditions
solid tumor (advanced stage)cutaneous squamous cell carcinoma (cSCC)urothelial carcinoma (UC)hepatocellular carcinoma (HCC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04272034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04272034.